Large Chinese state pharma group making antibiotics, vitamins (incl. bulk vitamin C) and OTC medicines.
Large Chinese state pharma group making antibiotics, vitamins (incl. bulk vitamin C) and OTC medicines.
Bulk vitamin C is a commodity whose price follows global supply, with China dominating output, so profit swings. Branded OTC medicines and antibiotics provide steadier but slower-growing income.
Moat: narrow (scale). Large-scale bulk API/vitamin manufacturing versus smaller regional producers.
Headquarters: Harbin, China · Employees: 10,039
Size Harbin Pharmaceutical (600664.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.78B, the 1292nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.81 on 18 Nov 2026.
Performance Over six months the shares gained 32.1%, against -7.3% for the median peer and -20.0% for the China market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 2.2% over the last twelve months (peer median +9.0%); the operating margin is 5.1% (peer median 7.8%).
Valuation It trades at 19.7× forward earnings against a peer median of 17.4× (8th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.0 points above its cost of capital (5.0% WACC).
Next results Next results expected around 14 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥16.3B | CN¥15.9B | CN¥16.1B | CN¥15.3B | CN¥13.7B |
| Revenue growth | — | -1% | +5% | +12% | — |
| Gross profit | CN¥4.36B | CN¥3.95B | CN¥4.35B | CN¥3.77B | CN¥3.10B |
| EBITDA | n/a | CN¥845M | CN¥1.22B | CN¥919M | CN¥871M |
| Net income | CN¥633M | CN¥362M | CN¥629M | CN¥395M | CN¥465M |
| Free cash flow | CN¥724M | CN¥289M | CN¥692M | CN¥864M | CN¥533M |
| Capital expenditure | CN¥176M | CN¥151M | CN¥101M | CN¥86.5M | CN¥89.6M |
| Total debt | CN¥2.56B | CN¥2.94B | CN¥3.78B | CN¥3.56B | CN¥3.43B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Harbin Pharmaceutical 600664.SS | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% |
| North China Pharmaceutical 600812.SS | $1.08B | -12% | -21% | 5% | n/a | 1.0% |
| Cspc Pharma 1093.HK | $12.0B | +10% | +25% | 28% | 9.1× | -10.7% |
| Northeast Pharmaceutical 000597.SZ | $895M | -14% | -6% | 3% | n/a | -7.6% |
| Zhejiang Medicine 600216.SS | $1.51B | -26% | -6% | 7% | 11.5× | -7.8% |
| Shandong Xinhua Pharmaceutical 000756.SZ | $1.01B | -17% | -5% | 4% | 20.0× | 0.5% |
| Zhejiang NHU 002001.SZ | $11.8B | -22% | +11% | 33% | 9.7× | -8.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600664.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -17.9% | +0.1% | 2nd lowest of 21 |
| 6-month return | +32.1% | -7.3% | 2nd highest of 21 |
| Distance from 52-week high | -51.2% | -32.8% | 4th lowest of 21 |
| Revenue growth (TTM) | +2.2% | +9.0% | 9th lowest of 21 |
| Operating margin | 5.1% | 7.8% | 9th lowest of 21 |
| Forward P/E | 19.7× | 17.4× | 8th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | -5.3% | 4.6% | 3rd least demanding of 15 |
| Growth delivered (Del g) | +8.2% | +8.6% | 8th highest of 15 |
| Hurdle (Req g minus delivered) | -13.4 pp | -6.4 pp | 5th least demanding of 15 |
| ROIC minus cost of capital | +6.0 pp | -2.9 pp | 4th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% | +8.2% |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 24.6× | 21.9% | +359.6% |
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.78B | -13% | -1% | 8% | 8.7× | -0.4% | -0.2% |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | n/a | n/a | n/a |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 13.0× | 1.2% | +7.8% |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 160.4× | n/a | n/a |
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 10.8× | -9.5% | +4.2% |
| Guobang Pharma 605507.SS | China | $1.82B | -6% | +3% | 12% | 15.7× | -6.0% | +7.4% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.83B | -25% | +17% | 33% | 13.0× | 5.4% | +29.1% |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% | +19.0% |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 74.9× | 35.3% | +9.2% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | n/a | n/a | n/a |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 17.4× | 3.7% | +9.9% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 22.0× | 11.3% | -11.0% |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% | +15.7% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |